Identification | Back Directory | [Name]
NLG919 | [CAS]
1402836-58-1 | [Synonyms]
CS-820 NLG919 GDC0919 GDC-0919 GDC 0919 NLG919, >=98% NLG919;NLG-919 IDO inhibitor 7 NLG-919 analogue NLG919;NAVOXIMOD NLG919 USP/EP/BP NLG919 (GDC-0919) NLG919(GDC-0919,Navoximod) 5H-Imidazo[5,1-a]isoindole-5-ethanol, α-cyclohexyl- alpha-Cyclohexyl-5H-imidazo[5,1-a]isoindole-5-ethanol 1-CYCLOHEXYL-2-(5H-IMIDAZO[5,1-A]ISOINDOL-5-YL)ETHANOL NLG-919; NLG 919; IDO INHIBITOR;GDC-0919;GDC 0919;GDC0919 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol 5-(2-Cyclohexyl-2-hydroxyethyl)-5H-imidazo[5,1-a]isoindole 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethanol NLG919 NLG919 1-CYCLOHEXYL-2-(5H-IMIDAZO[5,1-A]ISOINDOL-5-YL)ETHANOL | [EINECS(EC#)]
1592732-453-0 | [Molecular Formula]
C18H22N2O | [MDL Number]
MFCD26142661 | [MOL File]
1402836-58-1.mol | [Molecular Weight]
282.38 |
Chemical Properties | Back Directory | [Melting point ]
143 - 146°C | [Boiling point ]
524.6±33.0 °C(Predicted) | [density ]
1.27±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
Soluble in DMSO (up to 15 mg/ml) | [form ]
solid | [pka]
14.85±0.20(Predicted) | [color ]
White | [Stability:]
Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 3 months. |
Hazard Information | Back Directory | [Description]
(±)-NLG-919 is an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor (Ki = 7 nM; EC50 = 75 nM).1 (±)-NLG-919 inhibits IDO-induced T cell suppression and restores T cell response during allogenic mixed lymphocyte reactions in vitro (ED50s = 80 and 120 nM, respectively). In vivo, (±)-NLG-919 induces a 95% reduction in tumor volume when administered in conjunction with a pmel-1 T cell vaccine. Formulations containing (±)-NLG-919 are under investigation in clinical trials for treatment of glioblastoma, melanoma, pancreatic, and breast cancers.2 | [Uses]
NLG919 is a potent indoleamine-2,3-dioxygenase (IDO) pathway inhibitor and is suitable for the treatment of immunosuppression associated with cancer. | [target]
IDO pathway | [storage]
Store at -20°C | [References]
1) Mautino?et al.?(2013),?NLG919, a novel indolamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy;?Cancer Res.?73?issue 8 supplement?491
2) Li?et al.?(2014),?The indolamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma;?J. Immunother. Cancer?2?21
3) Meng?et al.?(2017),?Combinatorial antitumor effects of indoleamine 2,3-dioxygenase inhibitor NLG919 and paclitaxel in a murine B16-F10 melanoma model;?Int. J. Immunopathol. Pharmacol.?30?215 |
|
|